The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 3810477 in healthy male subjects.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
24
SGS Life Science Services - Clinical Research
Edegem, Belgium
Occurrence of any treatment-emergent adverse event assessed as drug-related by the investigator
Time frame: Up to Day 85
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)
Time frame: Up to Day 85
Maximum measured concentration of the analyte in plasma (Cmax)
Time frame: Up to Day 85
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.